EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Risk factors related to low-level viraemia in chronic hepatitis B patients receiving entecavir treatment

Zhong-Bin Li, Dan-Dan Chen, Yun-Fei Jia, Qing-Juan He, Li Cui, Feng-Xia Du, Yao-Jie Kang, Xin Feng, Mengwen He, Xue-Yuan Jin, Jing Chen, Yudong Wang und 3 weitere

Frontiers in Cellular and Infection Microbiology · 2024

DOI: 10.3389/fcimb.2024.1413589 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2024. Verfasst von Zhong-Bin Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Hepatology, the Fifth Medical Center of PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Guanine, Antiviral Agents, Viremia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

About 20% of on-treatment patients with chronic hepatitis B (CHB) experienced low-level viraemia (LLV), which is associated with persistent low-grade inflammation, fibrosis progression, and increased risk of hepatocellular carcinoma. We aimed to investigate the high-risk factors related to LLV.

Methods

In this retrospective study, patients receiving entecavir (ETV) treatment from January 2018 to January 2023 were enrolled, and were divided into a LLV (HBV DNA 20-2000 IU/mL) cohort and a complete virological response (CVR) (HBV DNA < 20 IU/mL) cohort according to the virological response at week 48 posttreatment. Treatment baseline characteristics were retrieved from electronic medical records. Multivariate logistic regression was performed.

Results

Totally, 1653 patients were enrolled, male patients accounted for 73.0%; the median age was 44 years; the mean HBV DNA level was 5.9 Log 10 IU/ml. Among them, 472 (28.6%) experienced LLV. Multivariate analysis showed that HBeAg positivity (OR = 2.650, 95% CI: 2.000-3.511, p < 0.001), HBV DNA ≥ 6.0 Log 10 IU/mL (OR = 1.370, 95% CI: 1.054-1.780, p = 0.019), qHBsAg ≥ 9000 IU/mL (OR = 4.472, 95% CI: 3.410-5.866, p < 0.001), cirrhosis (OR = 1.650, 95% CI: 1.234-2.207, P = 0.001), LSM ≥ 13.0 kPa (OR = 1.644, 95% CI: 1.203-2.246, p = 0.002), and PLT < 100×10 9 /L (OR = 1.450, 95% CI: 1.094-1.922, p = 0.010) at baseline were related to the development of LLV.

Conclusions

High HBV DNA/HBsAg quantification/LSM, low PLT, HBeAg positivity, and liver cirrhosis were high-risk factors associated with LLV in patients receiving entecavir treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicGuanineAntiviral AgentsViremiaHepatitis B virusDNA, ViralHumansMaleFemaleAdultRisk FactorsRetrospective StudiesMiddle AgedHepatitis B e AntigensLiver CirrhosisViral Load

Stichwörter der Autor:innen

complete virological responseeffectivenesshigh-risk factorlow-level viremianucleos(t)ide analogs

Substanzen

entecavirGuanineAntiviral AgentsDNA, ViralHepatitis B e Antigens

Autor:innen und Institutionen

  • Senior Department of Hepatology, the Fifth Medical Center of PLA General Hospital, Beijing, China.
  • Department II of Infectious Diseases (Hepatology), The Second People's Hospital of Jingzhou City, Jingzhou, China.
  • Department of Hepatobiliary & Gastrointestinal, Henan Province Hospital of Traditional Chinese Medicine, Zhengzhou, China.
  • Department II of Gastroenterology, The Eighth People's Hospital of Qingdao, Qingdao, China.
  • Department of Emergency, the Fifth Medical Center of PLA General Hospital, Beijing, China.
  • Department of Pharmacy, Medical Supplies Center of PLA General Hospital, Beijing, China.

Förderung

  • National Key Research and Development Program of China

Zitieren

APA

Li, Z. B., Chen, D. D., Jia, Y. F., He, Q. J., Cui, L., Du, F. X., Kang, Y. J., Feng, X., He, M., Jin, X. Y., Chen, J., Wang, Y., Ji, D., Lau, G., & Wu, S. G. (2024). Risk factors related to low-level viraemia in chronic hepatitis B patients receiving entecavir treatment. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2024.1413589

Vancouver

Li ZB, Chen DD, Jia YF, He QJ, Cui L, Du FX, et al. Risk factors related to low-level viraemia in chronic hepatitis B patients receiving entecavir treatment. Frontiers in Cellular and Infection Microbiology. 2024. doi:10.3389/fcimb.2024.1413589

BibTeX
@article{Li2024,
  author = {Li, Zhong-Bin and Chen, Dan-Dan and Jia, Yun-Fei and He, Qing-Juan and Cui, Li and Du, Feng-Xia and Kang, Yao-Jie and Feng, Xin and He, Mengwen and Jin, Xue-Yuan and Chen, Jing and Wang, Yudong and Ji, Dong and Lau, George and Wu, Shu-Gao},
  title = {Risk factors related to low-level viraemia in chronic hepatitis B patients receiving entecavir treatment},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2024},
  doi = {10.3389/fcimb.2024.1413589}
}
Kostenlos starten →